Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764579 | 0.79 | SMN1; SMN2 (0.46) | NPC1RAB9AKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL6570585 | 0.75 | NPC1 (0.64) | NPC1RAB9AOPRK1MAPTMGLL | |
| SCHEMBL3028818 | 0.72 | NPC1 (0.68) | NPC1RAB9AOPRK1MAPTMGLL | |
| SCHEMBL4201821 | 0.71 | NPC1 (0.66) | NPC1RAB9AOPRK1MAPTMGLL | |
| SCHEMBL27493267 | 0.70 | ALDH1A1 (0.61) | NPC1RAB9AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL13776053 | 0.69 | CTSK (0.51) | KMT2ASIRT2 | |
| SCHEMBL19120696 | 0.69 | MGLL (0.52) | NPC1RAB9AMAPTMGLLSMN1; SMN2 | |
| SCHEMBL5853278 | 0.68 | NPC1 (1.00) | NPC1RAB9AKMT2AMAPTMGLL | |
| SCHEMBL11766069 | 0.68 | NPC1 (0.72) | NPC1RAB9AOPRK1MAPTMGLL | |
| SCHEMBL4218396 | 0.68 | NPC1 (0.68) | NPC1RAB9AMGLLFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1414790-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003000653-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | NPC1 1387/4885RAB9A 1413/4885KMT2A 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.